Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.600 GeneticVariation group BEFREE Logistic regression analysis identified prior neurologic event (P = .046), nonelective surgery (P = .047), absence of coronary artery disease (P = .035), and preoperative angiotensin-converting enzyme inhibitor use (P = .029) to be associated with 30-day ipsilateral stroke risk, but contralateral ICA occlusion remained an independent predictor in that model (odds ratio, 2.29; P = .026). 31445827 2020
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.600 Biomarker group BEFREE In regard to clinical studies, treatment with Angiotensin Converting Enzyme (ACE) inhibitors and AT1 receptor antagonists exerts preventive and therapeutic effects on stroke. 31849284 2019
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.600 Biomarker group BEFREE Dual RAAS blockade with angiotensin-converting enzyme (ACE) inhibitor plus angiotensin receptor blockade (ARB) or ARB plus renin inhibition increases serious adverse events such as acute kidney injury and stroke. 30673886 2019
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.600 Biomarker group BEFREE We administered the National Adult Reading Test (NART, estimates premorbid or peak adult cognition) and the Revised Addenbrooke's Cognitive Examination (ACE-R; current cognition) at 1 and 12 months after stroke. 30875807 2019
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.600 Biomarker group BEFREE Most estimates revealed no effectiveness differences between classes; however, thiazide or thiazide-like diuretics showed better primary effectiveness than angiotensin-converting enzyme inhibitors: acute myocardial infarction (HR 0·84, 95% CI 0·75-0·95), hospitalisation for heart failure (0·83, 0·74-0·95), and stroke (0·83, 0·74-0·95) risk while on initial treatment. 31668726 2019
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.600 Biomarker group BEFREE History of stroke (odds ratio [OR]: 2·91, 95% confidence interval [CI]: 1·25-6·77) and use of angiotensin converting enzyme inhibitors/angiotensin receptor blockers (OR: 3·17, 95% CI: 1·28-7·84) were associated with rapid eGFR decline. 31168785 2019
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.600 Biomarker group BEFREE We recruited participants from inpatient and outpatient services with a lacunar or minor cortical ischaemic stroke (National Institutes of Health Stroke Scale score <8) and assessed current and premorbid cognitive functioning (Addenbrooke's Cognitive Examination-Revised (ACE-R), National Adult Reading Test (NART)), physical functioning (Timed Get Up and Go (TUG), 9-Hole Peg Test (9HPT)), dependency (modified Rankin Scale (mRS)), depression (Beck's Depression Inventory) in-person and remotely (Stroke Impact Scale). 30554134 2019
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.600 Biomarker group BEFREE Angiotensin converting enzyme (ACE) gene has emerged as an important player in the pathogenesis of hypertension and consequently stroke. 31802381 2019
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.600 Biomarker group BEFREE Association between Angiotensin-Converting Enzyme Inhibitors and Post-Stroke Aspiration Pneumonia. 31635965 2019
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.600 Biomarker group BEFREE Many patients who receive intravenous (i.v.) recombinant tissue-plasminogen activator (rt-PA) for acute cerebral ischemia were under angiotensin-converting enzyme inhibitors (ACE-Is) or angiotensin receptor blockers (ARBs) at stroke onset. 29549467 2018
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.600 Biomarker group BEFREE Prior stroke/TIA and/or PAD patients were less likely to receive evidence-based medical therapies (dual antiplatelet therapy: stroke/TIA= 88.6%, PAD= 86.6%, stroke/TIA+PAD= 85.7%, none= 92.2%, p<0.001; β-blockers: stroke/TIA= 77.1%, PAD= 72.1%, stroke/TIA+PAD= 71.9%, none= 80.8%, p<0.001; angiotensin-converting enzyme inhibitors/angiotensin receptor blockers: stroke/TIA= 86.3%, PAD= 83.6%, stroke/TIA+PAD= 83.2%, none= 87.1%, p=0.030) and to undergo percutaneous revascularization (stroke/TIA= 52.8%, PAD= 45.6%, stroke/TIA+PAD= 43.7%, none= 67.9%, p<0.001), despite more extensive coronary artery disease (three-vessel disease: stroke/TIA= 29.1%, PAD= 38.3%, stroke/TIA+PAD= 38.3%, none= 20.2%, p<0.001). 28627932 2018
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.600 Biomarker group BEFREE Amlodipine therapy was associated with 25% higher risk of heart failure (relative risk [RR]: 1.25, 95% confidence interval [CI], 1.05-1.49, P = .019) but 17% lower risk of stroke (RR: 0.83, [95% CI, 0.72-0.97], P = .009) without statistically significant effect on acute myocardial infarction (AMI) compared to major alternative antihypertensive therapy (MAAT), including β-blocker, diuretic, angiotensin-converting enzyme inhibitor, or angiotensin-receptor blocker. 29739234 2018
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.600 GeneticVariation group BEFREE We mainly observed a reduced risk of recurrent stroke in the subgroup of participants using an angiotensin-converting enzyme (ACE) inhibitor or a diuretic (I<sup>2</sup> statistic for subgroup differences 72.1%; P = 0.006). 30024023 2018
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.600 AlteredExpression group BEFREE These findings offer insight into ACE expression and activity in response to stroke, and further our understanding of ACE mechanisms. 29228591 2017
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.600 Biomarker group BEFREE Randomized, active controlled parallel group trials were included if they compared CCBs with α-blockers, β-blockers, angiotensin II receptor blockers, angiotensin-converting enzyme inhibitors, or diuretics, had a follow-up of ≥6 months, and had assessments of blood pressure (BP) and CV events [all-cause death, CV death, major CV events (myocardial infarction, MI; congestive heart failure, CHF; stroke; and CV death), MI, stroke, or CHF] in patients with baseline systolic/diastolic BP ≥140/≥90 mm Hg with either concomitant previous stroke and/or CAD. 26588586 2017
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.600 GeneticVariation group BEFREE Angiotensin I converting enzyme (ACE) insertion/deletion (I/D) polymorphism is thought to affect renin-angiotensin system (RAS) activity and development of cardiovascular disease; significant associations between I/D polymorphism and atherosclerosis, stroke, nephropathy, and early mortality were already found. 28190172 2017
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.600 Biomarker group BEFREE Furthermore, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and statins were of statistical significance for stroke risks.The majority of AF patients post-RFAs was of high stroke risk and received warfarin thromboprophylaxis in accordance with national guidelines. 29381974 2017
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.600 GeneticVariation group BEFREE Individuals harboring DD genotype of ACE I/D polymorphism are more predisposed to hemorrhagic stroke than ischemic stroke. 25015258 2015
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.600 GeneticVariation group BEFREE In pharmacogenetic analysis, the increased risk of stroke in subjects carrying G-6 was eliminated by concomitant treatment with an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker (P = .012 for interaction). 24732371 2014
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.600 GeneticVariation group BEFREE ACE and ADD1 gene are known to be associated with vascular complications leading to stroke susceptibility. 21194526 2011
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.600 Biomarker group RGD The effects of AT1 receptor blocker, telmisartan, and the ACE inhibitor, ramipril, were tested head-to head and in combination on stroke prevention in hypertensive rats and on potential neuroprotection in acute cerebral ischemia in normotensive rats. 21901125 2011
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.600 GeneticVariation group BEFREE The D allele of ACE I/D polymorphism may be a potential risk allele for stroke. 20300047 2010
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.600 AlteredExpression group BEFREE We also performed functional studies by measuring serum ACE protein levels and enzymatic activity in 27 controls, 68 patients with IS at baseline and 35 patients with IS 24 h after onset of stroke symptoms. 20402757 2010
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.600 GeneticVariation group BEFREE To study the influence of the APOE-epsilon4 allele and the ACE-I/D polymorphism on cognitive functioning after stroke. 20606435 2010
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.600 GeneticVariation group BEFREE This lack of association between stroke and ACE I/D polymorphism did not change in the presence of traditional risk factors (hypertension, diabetes mellitus, smoking, and dyslipidemia). 19596363 2009